The Targeted Intraoperative Radiotherapy United States phase IV trial (TARGIT-US Trial) studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery.
Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.
The TARGIT-US Trial is a follow-on trial of the TARGIT-A Trial. It was developed to facilitate enrollment of more U.S. patients studies evaluating intraoperative radiotherapy.
Dr. Holmes is a co-Principal Investigator of this national study.
Study Status: THIS STUDY IS NOW CLOSED TO ENROLLMENT. WE ARE CONTINUING TO FOLLOW THE PATIENTS FOR LONG-TERM OUTCOMES.
University of California, San Francisco
Helen Rey Breast Cancer Research Foundation
Telephone: 818-539-1985 FAX: 818-539-1985
Copyright © 2021 Helen Rey Breast Cancer Research Foundation - All Rights Reserved.
Founded in 2017